BACKGROUND: The possibility that opioid agonists can influence cancer recurrence is a subject of recent interest. Epidemiologic studies suggested that there were differences in cancer recurrence in breast and prostate cancer contingent on anesthetic regimens. In this study, we identify a possible mechanism for these epidemiologic findings on the basis of opioid receptor (MOR) regulation of Lewis lung carcinoma (LLC) tumorigenicity in cell and animal models. METHODS: We used human lung tissue and human non-small cell lung cancer (NSCLC) cell lines and evaluated MOR expression using immunoblot and immunohistochemical analysis. LLC cells were treated with the peripheral opioid antagonist methylnaltrexone (MNTX) or MOR shRNA and evaluated for proliferation, invasion, and soft agar colony formation in vitro and primary tumor growth and lung metastasis in C57BL/6 and MOR knockout mice using VisEn fluorescence mediated tomography imaging and immunohistochemical analysis. RESULTS: We provide several lines of evidence that the MOR may be a potential target for lung cancer, a disease with high mortality and few treatment options. We first observed that there is ϳ5to 10-fold increase in MOR expression in lung samples from patients with NSCLC and in several human NSCLC cell lines. The MOR agonists morphine and [D-Ala 2 , N-MePhe 4 , Gly-ol]enkephalin (DAMGO) increased in vitro LLC cell growth. Treatment with MNTX or silencing MOR expression inhibited LLC invasion and anchorage-independent growth by 50%-80%. Injection of MOR silenced LLC lead to a ϳ65% reduction in mouse lung metastasis. In addition, MOR knockout mice do not develop significant tumors when injected with LLC in comparison with wild-type controls. Finally, continuous infusion of the peripheral opioid antagonist MNTX attenuates primary LLC tumor growth and reduces lung metastasis. CONCLUSIONS: Taken together, our data suggest a possible direct effect of opiates on lung cancer progression, and provide a plausible explanation for the epidemiologic findings. Our observations further suggest a possible therapeutic role for opioid antagonists. (Anesth Analg 2011;112:558 -67) 
T he effect of anesthetics on cancer recurrence has been a subject of recent interest in the anesthesia literature. [1] [2] [3] [4] Although the cause of these epidemiologic findings remains unclear, there is an evolving experimental literature suggesting that opiates affect tumor growth. Both we and Gupta et al. have shown that clinically relevant concentrations of opiates can cause endothelial cell proliferation and migration in vitro, and the selective peripheral opioid receptor (MOR) antagonist, methylnaltrexone (MNTX), inhibits angiogenesis, a process required for in vivo tumor growth. [5] [6] [7] [8] In addition, morphine, at clinically relevant concentrations, promotes human breast cancer growth in animal and in vitro models. 8 On the other hand, animal experiments using high concentrations of morphine demonstrated inhibition of tumor metastases and reduced survival in animal models of breast cancer. 9 Some experimental data suggest that opioids inhibit lung tumor metastasis after laparotomy in rodents. 10 -12 These results were explained, in part, by morphine's potential inhibitory effects on natural killer cell activity. 11, [13] [14] [15] Evidence supporting an immunomodulatory and sympathoneural effect on tumor progression emerges from a recent study in rodents. 16 Given the conflicting reports on morphine's effects on lung cancer progression, we undertook a series of in vitro and in vivo experiments to examine the direct effect of the MOR in lung cancer progression using the well-established model of Lewis lung carcinoma (LLC). 17, 18 We hypothesized that the activation of the MOR during surgery might be a plausible explanation for the differences in recurrence rates noted in the epidemiologic studies. Importantly, our observations of attenuation of tumor growth and metastasis occurred absent exogenous opioids, supporting an underlying role of the MOR in lung cancer progression. Taken together, our data suggest a possible direct effect of opioids on lung cancer progression, and provide a plausible explanation for the epidemiologic findings. Our observations further suggest a possible therapeutic role for opioid antagonists that merits further evaluation.
METHODS
The experiments presented in this manuscript are a continuum of cellular, tissue, and in vivo studies designed to elucidate the functional role of the MOR in lung cancer. Cellular studies include determining with immunoblotting techniques the relative levels of MOR expression in mouse LLC cells, various human non-small cell lung cancer (NSCLC) cells, and nontumorigenic human BEAS-2B cells. The role of opioid agonists (morphine and [d-Ala 2 , N-MePhe 4 , Gly-ol]-enkephalin [DAMGO] ) in LLC cellular proliferation and the MOR (MOR shRNA) in LLC cellular proliferation, invasion, and anchorage-independent growth were also assessed using in vitro assays to determine potential mechanisms of in vivo tumor growth and metastasis. Tissue studies include determining the relative MOR immunohistochemical staining intensity from lung cancer and normal patient samples. In vivo studies include determining the role of MOR in LLC mouse primary flank tumor and lung metastasis models using MOR silencing of LLC cells, continuous infusion of the peripheral MOR inhibitor, MNTX, and use of MOR knockout mice.
Cell Culture and Reagents
Human NSCLC cell lines H522, H1703, H1993, SW1573, H1437, H358, control BEAS-2B, and mouse LLC cells were obtained from ATCC (Walkersville, MD). LLC cells with stable GFP/RFP expression were a generous gift from Dr. Ralph R. Weichselbaum and Dr. Rosie Xing. Normal human bronchial epithelial cells were purchased from Lonza Group (Walkersville, MD). Cells were cultured in Roswell Park Memorial Institute (RPMI) complete medium (Cambrex, East Rutherford, NJ) at 37°C in a humidified atmosphere of 5% CO 2 , 95% air, with passages 6 to 10 used for experimentation. Unless otherwise specified, reagents were obtained from Sigma (St. Louis, MO). N-methylnaltrexone bromide or MNTX was purchased from Mallinckrodt Specialty Chemicals (Phillipsburg, NJ). Rabbit anti-MOR-1 antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA) and GeneTex (Irvine, CA). Reagents for SDS-PAGE electrophoresis were purchased from Bio-Rad (Richmond, CA) and Immobilon-P transfer membrane from Millipore (Millipore Corp., Bedford, MA). Secondary horseradish peroxidase (HRP)-labeled antibodies were purchased from Amersham Biosciences (Piscataway, NJ). For immunoblotting, cellular and tissue homogenates were run on SDS-PAGE in 4%-15% polyacrylamide gels, transfer onto Immobilon TM membranes, and developed with specific primary and secondary antibodies. Visualization of immunoreactive bands was achieved using enhanced chemiluminescence (Amersham Biosciences).
Use of shRNA
The shRNA was used to inhibit the protein expression of the MOR in LLC cells by interfering with MOR mRNA. The shRNA for mouse MOR was purchased from Santa Cruz Biotechnology. LLC were transfected with shRNA using FuGENE HD TM as the transfection reagent (Roche Applied Sciences, Penzberg, Germany) according to the protocol provided by Roche. Cells (ϳ40% confluent) were serumstarved for 1 hour, followed by incubation with siRNA for 6 hours in serum-free media. Serum-containing media were then added (10% serum final concentration) for 42 hours and puromycin selection reagent was added. 19 MOR was efficiently silenced in LLC cells (inset of Fig. 1D ).
LLC Cell Proliferation Assay
For measuring in vitro cell growth, LLC [5 ϫ 10 3 cells/well pretreated with control or MOR shRNA were incubated with 0.2 mL of serum-free media containing either vehicle (control), 1 nM morphine, or 1 nM DAMGO for 24 hours at 37°C in 5% CO 2 /95% air in 96-well culture plates. The in vitro cell proliferation assay was analyzed by measuring increases in cell number using the CellTiter96 TM MTS assay (Promega, San Luis Obispo, CA) and read at 492 nm. Each assay was set up in triplicate, repeated at least 5 times, and analyzed statistically by Student t test (with statistical significance set at P Ͻ 0.05).
LLC Cell Invasion Assay
Twenty-four transwell units with 8-M pore size coated with Matrigel (QCM ECMatrix Cell Invasion Assay kit, Millipore, Billerica, MA) were used for monitoring in vitro cell invasion, as we have previously described. 20 LLC cells (ϳ1 ϫ 10 4 cells/well) were plated with various treatments (MNTX, control shRNA, MOR shRNA) to the upper chamber, and various concentrations of media with serum were added to the lower chamber. Cells were allowed to invade through the Matrigel and pores for 18 hours. Cells from the upper and lower chambers were quantitated using the CellTiter96 TM MTS assay (Promega, San Luis Obispo, CA) and read at 492 nm. The percentage invasion was defined as 100 times the number of cells in the lower chamber divided by the number of cells in both the upper and lower chambers. Each assay was set up in triplicate, repeated at least 5 times, and analyzed statistically by Student t test (with statistical significance set at P Ͻ 0.05). The results of the in vitro invasion assays provide a potential explanation as to how the LLC mouse primary tumor cells can metastasize to the lung by invading through stromal and endothelial barriers. 21 
Soft Agar Colony Formation Assay
Ninety-six well units (Cytoselect TM 96 well Cell Transformation Assay, Cell Recovery Compatible, Colorimetric (Cell Biolabs, Inc., San Diego, CA) were used for monitoring in vitro anchorage-independent tumor cell growth. 22, 23 LLC cells (ϳ1 ϫ 10 3 cells/well) were plated with various treatments (control or shRNA) to a base agar matrix layer and monitored for 6 to 8 days. Formation of cell colonies was quantitated using MTT in detergent solution and absorbance was measured at 570 nm in a 96-well microtiter plate reader. Each assay was set up in triplicate, repeated at least 5 times, and analyzed statistically by Student t test (with statistical significance set at P Ͻ 0.05). The results of the soft agar colony formation assays in this study provide a potential explanation as to how the LLC mouse primary tumor cells can metastasize to the lung by anchorageindependent growth in the bloodstream.
In Vivo LLC Tumor Studies
After approval of the Institutional Animal Care and Use Committee (IACUC), 3 different in vivo experiments were performed. For all 3, the cell lines used were LLC and stable GFP/RFP expressing LLC, as described above. All mice were 8-to 12-week-old females obtained from Jackson , and to a lesser extent, squamous cell carcinoma (SCC). MOR-specific brown staining intensity from 10 patient samples per group was analyzed with a statistically significant difference (P Ͻ 0.05) between normal and BAC, Adeno, or SCC. B, MOR immunoblot analysis of cell lysates from human NSCLC adneocarcinoma cell lines (H522, H1703, H1993, H1437), human NSCLC BAC cell lines (SW1573, H358), noncancerous BEAS-2B, normal human bronchial epithelial cells (NHBEC), and tissue homogenates from MOR knockout mouse brain and C57BL/6 mouse brain. There is increased MOR expression in several human NSCLC cell lines. C, Stable control shRNA or MOR-1 shRNA-transfected LLC cells were analyzed for opioid agonist-mediated proliferation using a MTS proliferation assay. There is a statistically significant difference (P Ͻ 0.05, indicated by an asterisks) between control and [D-Ala 2 , N-MePhe 4 , Gly-ol]-enkephalin (DAMGO) (1 nM, 24 hours) or morphine (1 nM, 24 hours)-treated LLC cells with n ϭ 3 per condition. Stable silencing (shRNA) of the opioid receptor blocks opioid agonist-induced LLC proliferation. See the Methods section for experimental details. D, LLC cells were transfected with either control shRNA or MOR-1 shRNA, selected with puromycin, and MOR protein expression analyzed (panel C, inset). Cells were then analyzed for in vitro invasion with media containing 1%, 5%, or 10% serum, n ϭ 3 per condition. There is a significant reduction in invasion (P Ͻ 0.05) between control shRNA and MOR-1 shRNA-transfected cells for all conditions tested. E, The peripheral MOR antagonist, methylnaltrexone (MNTX), inhibits LLC cell invasion. LLC cells were treated with 0-, 10-, or 100-nM MNTX and invasion assays performed. There is a statistically significant difference (P Ͻ 0.05) between groups with n ϭ 3 per condition. F, Stable control shRNA or MOR-1 shRNA-transfected LLC cells were analyzed for anchorage-independent growth using a soft agar colony formation assay. There is a statistically significant difference (P Ͻ 0.05) between groups with n ϭ 3 per condition. See the Methods section for experimental details.
Laboratories (Bar Harbor, ME). At the end of each experiment, lungs and primary tumors (if present) were collected, fixed in formalin, and embedded in paraffin. All animal procedures were performed in accordance with the guidelines provided by the IACUC of the University of Chicago. For IV injection of LLC (metastatic tumor model), stable GFP/RFP expressing LLC cells were treated with either control or MOR shRNA. For each cell treatment, 1.0 ϫ 10 5 cells were injected into the jugular vein of wild-type C57BL/6 mice. For the subcutaneous tumor model using MOR knockout mice, 1.0 ϫ 10 6 LLC cells were injected subcutaneously into the flank of C57BL/6 wild-type or MOR knockout mice. Tumor nodules were measured regularly using calipers once they became visible, and tumor volume Vt (mm 3 ) was calculated using the ellipsoid formula A 2 ϫ B ϫ /6, where A represents the smaller diameter. 24 For the subcutaneous tumor model using wildtype mice and MNTX, 1.0 ϫ 10 6 LLC cells were injected subcutaneously into the flank of C57BL/6 wild-type mice. Once tumors reached an average volume of 100 mm 3 , Alzet osmotic pumps (100 L, 0.25 L/hr) containing either MNTX or phosphate-buffered saline were implanted subcutaneously on the back. The pumps delivered continuous doses of drug or vehicle over the course of 12 days, during which time the tumors were measured regularly and their volume was calculated.
Quantification of Lung Metastasis
To characterize metastasis from primary tumors growing in mouse hind flank (see above), lungs from wild-type, MOR knockout, and MNTX-treated mice were formalin fixed, 5-paraffin sections were obtained and hydrated, and epitope retrieval performed (DakoCytomation Target Retrieval Solution, pH ϭ 6.0, Dako, Carpinteria, CA). The sections were then histologically evaluated by hematoxylin and eosin (H & E) staining and photographed (100ϫ) using a Leica Axioscope (Bannockburn, IL). Slide images were analyzed using ImageJ (National Institutes of Health [NIH], Washington, DC) software. Stained tumors with area Ͼ30,000 m 2 were quantified, and the pixel variable was normalized with the variables of the microscope magnification used.
Human Lung Immunohistochemistry
Immunohistochemical analysis was performed on human tissue microarrays (TMA, RayBiotech, Inc., Norcross, GA). For antigen retrieval, sections were heated in Tris-EDTA buffer (pH ϭ 9) for 10 minutes and incubated for 1 hour at room temperature with mouse monoclonal MOR1 antibody (1:100) (GeneTex Inc., Irvine, CA). This was followed by 30 minutes incubation with goat antirabbit HRP-conjugated immunoglobulin G (EnVisionTMϩ, Dako). Slides were developed for 5 minutes with 3,3Ј-diaminobenzidene chromogen and counterstained with hematoxylin.
Quantification of MOR Expression in Human Lung Samples
MOR immunohistochemical staining was performed on tissue microarrays (TMA, RayBiotech, Inc.) containing 10 cases of human bronchioloalveolar carcinoma, adenocarcinoma, or squamous cell carcinoma lung cancer and adjacent normal tissue. The microscopic images of each slide were scanned and analyzed using Chromavision Automated Cellular Imaging System (ACIS, Clarient, Aliso Viejo, CA) in a digital format that accounts for all individual microscopic fields. Areas of interest were outlined and the intensity was quantified by the software and converted to a score over a set of defined parameters. Brown integrated optical density (IOD) per 10 2 was used as the unit of measurement. 25 
Quantification of Lung Metastasis in Mice
To characterize metastasis from primary tumors growing in mouse hind flank (see above), lungs from wild-type, MOR knockout, and MNTX-treated mice were formaline fixed. Five-micrometer paraffin sections were subjected to H & E histostaining to evaluate the presence or absence of tumors. Metastasis was defined as a presence of small clusters of tumor cells detected by H & E staining. 26 The tumors are identifiable and histologically distinct from regular tissue. The sections of entire lungs were photographed (1.25ϫ) using a Leica Axioscope (Bannockburn, IL) and analyzed. Slide images were processed using ImageJ (NIH) software. 27 Perfectly circular metastatic lesions that were Ͼ0.1 mm in radius were defined as macrometastasis, and micrometastasis was defined as a tumor deposit Ͻ0.1 mm in radius, but larger than 0.05 mm. Staining with the radius Ͻ0.05 mm was too insignificant to quantify. Hence, the method is sensitive enough to identify larger metastasis but fails to account for metastasis less than 0.05 mm because of difficulty in differentiating from the normal tissue.
In Vivo Murine Fluorescent Imaging
To visualize GFP/RFP-labeled LLC growth in mouse lung, we used the Olympus OV-100 Small Animal Imaging System (Olympus Corp., Tokyo, Japan) for imaging to compare tumor development in mice inoculated with MOR-1 silenced as well as control LLC tumor cells. 24, 28 The OV-100 imaging system used in our studies is equipped with a highly sensitive Hamamatsu Electron Multiplying (EM) CCD camera. Two weeks after inoculation with tumor cells, lungs were imaged ex vivo to evaluate the number of microtumors in the lungs. To visualize and quantify primary flank tumor growth changes associated with MOR in real-time, we imaged mice with VisEn fluorescence mediated tomography. VisEn FMT is optimized for probes incorporating commonly used near-infrared (NIR) fluorochromes in both the 680-nm and 750-nm channels with mouse-handling features for high-throughput imaging. We have used Prosense 680 and MMPsense750 NIR probes (VisEn Medicals, Woburn, MA) to visualize and quantify changes in tumor growth. MOR knockout and wild-type control mice, inoculated with tumor cells, were injected (IV) with probes (2 nM) at 2 weeks after tumor cell inoculation and imaged at 24 hours after probe injection.
Statistical Analysis
Data are expressed as means Ϯ sd. Student t test using 2-tailed analysis of 2 groups with unequal variance was used for data analysis with a P value of Ͻ0.05 considered statistically significant.
RESULTS
Our initial observations in this study demonstrated increased MOR expression in lung samples from patients with NSCLC, a disease with few treatment options that accounts for 85% of all lung cancers 29 (Fig. 1A) . These data are consistent with positron emission tomography imaging data in humans demonstrating receptors in 3 major types of lung cancer. 30 We next examined several human NSCLC cell lines and observed similar increases in MOR expression ( Fig. 1B) . To test the functional significance of MOR expression in vitro, we inhibited MOR expression in mouse LLC using shRNA and observed that these cells failed to respond to opioid agonist (DAMGO or morphine, 1 nM, 24 hours) mediated increase in proliferation (ϳ35%-50%, P Ͻ 0.05, Fig. 1C ). Furthermore, MOR-silenced LLC exhibited less invasive properties (ϳ45%-70%) (Fig. 1D ). The use of MNTX, at physiologically relevant concentrations (10 nM, P ϭ 0.013; 100 nM, P ϭ 0.002), 31 also inhibited LLC invasion (ϳ40%-75%), indicating the importance of MOR in this cancer process (Fig. 1E ). Attenuating MOR expression in LLC also reduced anchorage-independent growth (ϳ35%), a measure of tumorigenic potential (Fig. 1F ). We next hypothesized that MOR shRNA LLC cells would exhibit less-invasive properties in vivo.
Using a mouse model of lung metastasis with IV injection of LLC that expresses GFP/RFP, we observed reduced lung metastasis size with MOR silencing ( Fig. 2A ) using lung fluorescence intensity (P ϭ 0.012) ( Fig. 2B ) and quantitation of H & E stained lung sections (P ϭ 0.004) (Fig. 2C) .
Having previously demonstrated that opiates promote angiogenesis both in vitro and in vivo, [5] [6] [7] we determined whether MOR could have an additional effect on the tumor microenvironment. To test this, we injected LLC cells into the hind flank of wild-type and MOR knockout mice, and tumor formation was examined in vivo using VisEn FMT imaging of tumor volume at 12 days after visible tumor formation after injection of Prosense680 32,33 (activated by cathepsins, known to be up-regulated in cancer 34 ) NIR probe (Fig. 3A) . Quantitation of in vivo fluorescence indicated virtually no tumor formation in the MOR knockout mouse (P Ͻ 0.001) (Fig. 3B) . These results were independently verified by direct physical measurement using calipers to measure tumor volume (P Ͻ 0.001) (Fig. 3C ). We maintained MOR knockout mice for up to 12 weeks without a significant visible tumor, suggesting that the MOR, even absent exogenous opioids, may play a role in tumor progression.
Given our data indicating the importance that MOR plays in several cancer-related processes, we hypothesized that MNTX could reduce LLC tumor size and metastasis in our animal models. Continuous infusion of MNTX (10 mg/kg/day, Alzet mini pumps) for 2 weeks after visible primary flank tumor formation in C57BL/6 mice attenuated further tumor growth (P Ͻ 0.05) (Fig. 4A) . These same mice were evaluated for lung metastasis from the primary flank tumor using H & E staining of excised formalin-fixed lung sections (Fig. 4B) . Our data indicate that MNTX substantially inhibited lung metastasis (P ϭ 0.018) (Fig. 4C) , providing further evidence that MOR is a novel regulator of lung cancer progression. Mice treated with naltrexone infusions exhibited a similar effect on tumor growth and metastasis, suggesting that this is not a drug-specific effect of MNTX (data not presented). These studies were performed using MNTX because opioids are commonly given to cancer patients and MNTX is the only parenterally administrated peripheral opiate antagonist clinically available.
DISCUSSION
Our observations demonstrate an effect of the MOR on cancer growth and metastasis. That our observations may have clinical relevance is suggested by recent epidemiologic data demonstrating that anesthetic technique (i.e., use of opiates) may play a role in tumor dissemination and recurrence. 1 In a retrospective study of 225 patients who had surgery for prostate cancer, there was a significant difference in the rate of tumor recurrence contingent on the type of anesthesia used. 3 Patients receiving a combined epidural/general anesthetic had 61% less recurrence (P Ͻ 0.0003) than did those who received a general anesthetic with opiates for analgesia during their primary surgery. A small retrospective study in breast cancer had similar findings. 4 Several recent retrospective analyses also point to a possible effect of anesthetic choice on cancer recurrence, although the results are less clear cut. A small Canadian study 35 of 99 patients found no difference in recurrence between patients receiving adjunctive epidural anesthesia with opiates and those receiving general anesthetics. However, another retrospective study 36 of 669 patients undergoing colorectal surgery failed to demonstrate an association between epidural use and cancer recurrence, although there appeared to be some benefit in patients older than 64 years. A third study 37 from the Veterans Affairs Cooperative Study on patients undergoing colon cancer resection showed a more complicated effect, demonstrating some benefits of an epidural in patients without metastases. Additional support for an effect of anesthetics on cancer progression comes from a study on melanoma. When general anesthesia was used for primary excision, there was a decrease in survival rate (relative risk of 1.46, P Ͻ 0.0001) in comparison with local anesthetic. 38 Thus, while retrospective epidemiologic studies suggest a potential difference between epidural and general anesthetics in various malignancies, they do not define a mechanism. Furthermore, these retrospective studies cannot distinguish between a putative beneficial effect of the regional anesthetic or a possible oncogenic effect of the opiate. A large multicenter prospective randomized trial investigating the influence of type of anesthesia on breast cancer recurrence is currently underway. 39 A recent review suggests potential immunologic, endocrine, or proangiogenic effects of anesthetics and opioids as explanations for this difference. 1 Although the potential mechanisms for an effect of anesthetics on cancer recurrence may be complex and multifactorial, 1, 40 we focused on exploring the direct effect of opioids on tumor growth and progression. Our findings do not preclude other explanations such as attenuation of the neuroendocrine stress response or immunologic effects. However, a direct action of opioids is more temporally consistent with an effect in the perioperative period than is the hypothesis of an effect on immune surveillance.
The current study provides a possible explanation for the epidemiologic findings of an anesthetic effect in prostate and breast cancer. Our most dramatic finding was that we did not observe substantial LLC tumor growth in the MOR knockout mouse (Fig. 3) . Although wild-type mice developed lethal tumors 12 days after injection, none of the MOR knockout mice developed tumors even after 12 weeks. One potential explanation for this finding is that the MOR may be required in angiogenesis, an essential process for in vivo tumor growth. We have previously published that the proangiogenic effects of opioid agonists appear to be due to reciprocal transactivation of the vascular endothelial growth factor (VEGF) receptor through a mechanism that involves Src activation. 5 We further demonstrated that the peripherally acting opiate receptor antagonist MNTX, which antagonizes the peripheral effects of opiates while preserving centrally mediated analgesia, inhibits opiate-and VEGF-induced angiogenesis through direct inhibition of MOR and activation of tyrosine phosphatase activity. [5] [6] [7] MNTX has a synergistic effect with 5-fluorouracil, bevacizumab, and mTOR inhibitors on inhibition of angiogenic events through attenuation of different components of a common VEGF-induced signal transduction pathway. 6, 7 Beyond its effect on the cell membrane, there may also be specific MNTX, but not naltrexone, mediated effects on Src activation because silencing the RPTP phosphatase blocks MNTX (but not naltrexone) inhibition of VEGF-induced Src phosphorylation. 6 Our results in knockout mice are supported by several lines of in vivo and in vitro evidence. We demonstrated increased MOR expression in lung samples from patients with NSCLC and in several human NSCLC cell lines (Fig.  1) . Because MOR overexpression is not necessarily a prerequisite for tumor propagation, our laboratory is currently examining the exact role of MOR overexpression with regard to propagation of tumorigenic properties. Beyond the demonstration of increased MOR expression in tumor samples, treatment of LLC with the MOR agonists morphine and DAMGO increases in vitro cellular growth (Fig.  1 ). Blocking MOR function (MNTX or shRNA) substantially reduces in vitro measures of LLC tumorigenicity such as invasion and anchorage-independent growth (Fig. 1) . Our in vivo studies demonstrate that IV injection of LLC without MOR expression leads to a ϳ65% reduction in mouse lung metastasis (Fig. 2) . Finally, continuous infusion of MNTX (10 mg/kg/day) attenuates primary LLC tumor growth and reduces lung metastasis (Fig. 4) . We have performed preliminary studies on plasma concentrations of MNTX in several of the autopsied animals (data not shown). Plasma concentrations are similar to the doses we achieved in our endothelial barrier function studies 41 and are consistent with what may be achieved clinically with parenteral administration of MNTX.
Whether opioids facilitate oncogenesis beyond the surgical setting is unclear. One randomized trial of patients receiving either intrathecal opiates or comprehensive (i.e., systemic opiate) cancer care showed a dramatic difference at 180 days (54% vs. 37%) in survival in those patients receiving intrathecal opiates. 42 On the other hand, there is no compelling clinical evidence that either opiates or opiate antagonists affect the development of new tumors. We examined this hypothesis in a retrospective study of new tumors from patients receiving methadone maintenance or chronic implanted naltrexone. Although the study was retrospective and small, some 4000 patient years in all, we did not see a signal suggesting an effect of methadone or naltrexone on the development of new tumors. 43 The perioperative period may be special in several regards. First, opioid agonists are routinely given parenterally in the perioperative period and often in high doses. Second, in cases of tumor surgery, recent data suggest that there may be a release of tumor cells into the circulation. 44 -47 Finally, there may be direct effects of opioids on barrier function, which may allow those tumor cells liberated during surgery to directly breach the endothelial barrier, potentially causing metastasis to distant locations. 41 We have previously demonstrated concentration-dependent in vivo and in vitro differences in barrier integrity mediated by morphine and other opioids.
Beyond their role in anesthetics, our findings of MOR regulation of lung cancer are novel and point to a possible therapeutic role of opioid antagonists. NSCLC has a poor prognosis and considerable heterogeneity. A number of novel therapeutic options have emerged for NSCLC, such as epidermal growth factor receptor inhibition 48 and VEGF inhibition. 49 However, the response to these therapeutics is only short-lived in a majority of patients. 29, 50 Furthermore, many lung cancer patients take opioids, and this may potentially affect the growth and progression of lung cancer tumors.
Certain caveats apply to our work. First, LLC is among the robust tumors in both growth and response to drugs. 51 Whether our findings are applicable to other tumors or to humans is not known. Although we have not explored a potential role of opiate antagonists in other models of human malignancy, the original study by Gupta et al. was performed in breast cancer xenografts. Additionally, a recently presented study of nude mice inoculated with human squamous head and neck cancer cells demonstrated that chronic naltrexone treatment inhibited growth of these tumors by up to 84% at 3 weeks (P Ͻ 0.001). Thus, we cannot exclude a more general role for our observations. 52 Additionally, the work presented in this communication deals predominantly with the effects of MOR antagonists. The effect of chronic opioid administration is not specifically assessed. There is considerable evidence that chronic exposure to exogenous opioids changes the response in both brain and gut. Whether the MOR expression changes with chronic exposure in tumor cells or endothelial cells is unknown. Finally, our findings do not preclude other effects of opioids, either directly or indirectly. There is an emerging literature on the effects of opioids on the immune system. However, a direct effect such as we define could explain the fact that these effects occur during surgery with brief exposure.
Taken as a whole, these results indicate that the MOR promotes a mouse model of lung cancer growth and metastasis. In conjunction with our findings that opioids alter endothelial barrier integrity and facilitate angiogenesis, our observations (many of which were made without exogenous opioids) suggest a possible explanation of the epidemiological studies demonstrating an effect of anesthetics in patients undergoing cancer surgery. Whether these results can be extended into the therapy of human malignancy remains to be determined. However, our observations do suggest that further study of MOR as a potential therapeutic target and/or MOR antagonists as a potential therapeutic strategy is merited.
